Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flutemetamol F 18

Drug Profile

Flutemetamol F 18

Alternative Names: 18-F Flutemetamol; [18F]flutemetamol; AH-110690; F-18 PiB; F18 flutemetamol; Flutemetamol F18; Flutemetamol F18 Injection; GE 067; Pittsburgh compound B; Vizamyl

Latest Information Update: 10 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pittsburgh
  • Developer GE Healthcare; University of Pittsburgh
  • Class Aniline compounds; Imaging agents; Small molecules; Thiazoles
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 02 Nov 2016 GE healthcare completes a phase III trial for Alzhemier's disease (diagnosis) in the Netherlands (EudraCT2012-002303-18)
  • 01 Sep 2014 Registered for Alzheimer's disease (Diagnosis) in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top